1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Post-Myocardial Infarction - Pipeline Review, H1 2013

Post-Myocardial Infarction - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 34 pages

Post-Myocardial Infarction - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Post-Myocardial Infarction - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post-Myocardial Infarction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Myocardial Infarction. Post-Myocardial Infarction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Post-Myocardial Infarction.
- A review of the Post-Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post-Myocardial Infarction pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Post-Myocardial Infarction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post-Myocardial Infarction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Post-Myocardial Infarction - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Post-Myocardial Infarction Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Post-Myocardial Infarction 7
Post-Myocardial Infarction Therapeutics under Development by Companies 9
Post-Myocardial Infarction Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Post-Myocardial Infarction Therapeutics - Products under Development by Companies 13
Post-Myocardial Infarction Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Post-Myocardial Infarction Therapeutics Development 15
Proteonomix, Inc. 15
miRagen Therapeutics, Inc. 16
Post-Myocardial Infarction - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
MGN-1374 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
anakinra - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
StromaCel - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Post-Myocardial Infarction Therapeutics - Drug Profile Updates 26
Post-Myocardial Infarction Therapeutics - Dormant Products 27
Post-Myocardial Infarction - Product Development Milestones 28
Featured News and Press Releases 28
Sep 28, 2010: Trophos Initiates Clinical Development Of TRO40303 28
Jan 26, 2010: CellProthera Achieves A Revolutionary Breakthrough In The Treatment Of Myocardial Infarction With The Support Of The Alsace Region And The Alsace BioValley biocluster 28
Mar 02, 2009: RegeneRx Completes Enrollment And Dosing Of Phase I Safety Trial For Potential Heart Drug 29
Sep 22, 2008: RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial 30
Sep 08, 2008: RegeneRx Successfully Completes Phase IA Clinical Trial 30
Jul 03, 2008: RegeneRx Completes Enrollment And Dosing Of Phase IA Safety Trial For Potential Heart Drug 30
Feb 15, 2008: King Pharmaceuticals Announces Altace Tablets Launch 31
May 19, 2007: King Pharmaceuticals Reports Efficacy of Altace 20mg and Efficacy of a Combination of Altace 20mg and Hydrochlorothiazide 25mg for 24-Hour Blood Ppressure Control 31
May 08, 2007: King Pharmaceuticals Announces Plan to Present Results From Phase III Clinical Trial Evaluating Altace As Monotherapy And In Combination With Hydrochlorothiazide At The American Society Of Hypertension Annual Meeting 32
Apr 19, 2007: King Pharmaceuticals Announces Plan to Report Positive Data From Phase III Clinical Trial Evaluating the Combination of Altace With Hydrochlorothiazide 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables


Number of Products Under Development for Post-Myocardial Infarction, H1 2013 7
Products under Development for Post-Myocardial Infarction - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Proteonomix, Inc., H1 2013 15
miRagen Therapeutics, Inc., H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Post-Myocardial Infarction Therapeutics - Drug Profile Updates 26
Post-Myocardial Infarction Therapeutics - Dormant Products 27

List of Figures


Number of Products under Development for Post-Myocardial Infarction, H1 2013 7
Products under Development for Post-Myocardial Infarction - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Myocardial Infarction - Pipeline Review, H2 2016

Myocardial Infarction - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Myocardial Infarction - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H2 2016’, provides an overview of the Myocardial Infarction pipeline landscape. ...

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016 ...

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein A I (APOA1) ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.